Elanco Animal Health (NYSE:ELAN) and Unicycive Therapeutics (NASDAQ:UNCY) Financial Comparison

Unicycive Therapeutics (NASDAQ:UNCY) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Volatility and Risk

Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.

Profitability

This table compares Unicycive Therapeutics and Elanco Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Elanco Animal Health	-3.96%	8.13%	3.99%

Insider and Institutional Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Unicycive Therapeutics and Elanco Animal Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	195.36	-$26.56 million	($1.75)	-2.73
Elanco Animal Health	$4.71 billion	2.38	-$232.00 million	($0.41)	-54.85

Unicycive Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Unicycive Therapeutics and Elanco Animal Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1	1	5	0	2.57
Elanco Animal Health	1	2	9	1	2.77

Unicycive Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 293.08%. Elanco Animal Health has a consensus target price of $29.09, suggesting a potential upside of 29.35%. Given Unicycive Therapeutics’ higher possible upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Elanco Animal Health.

Summary

Elanco Animal Health beats Unicycive Therapeutics on 8 of the 15 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.